Papillary thyroid carcinoma with a high tumor mutation burden has a poor prognosis

• DOI: 10.1016/j.intimp.2020.107090
• Publication Date: 2020-10-19T17:58:07Z
• Authors: Zhenyu Xie; Xin Li; Yu Lun; Yuzhen He; Song Wu; Shiyue Wang; Jianjian Sun; Yuchen He; Shijie Xin; Jian Zhang
• Keywords: Male; DNA Mutational Analysis; Computational Biology; Kaplan-Meier Estimate; Middle Aged; Prognosis; 3. Good health; Gene Expression Regulation, Neoplastic; 03 medical and health sciences; Lymphocytes, Tumor-Infiltrating; 0302 clinical medicine; Thyroid Cancer, Papillary; Databases, Genetic; Mutation; Biomarkers, Tumor; Humans; Regression Analysis; Female; Thyroid Neoplasms

Tumor mutation burden (TMB) as a prognostic marker for immunotherapy has shown prognostic value in many cancers. However, there is no systematic investigation on TMB in papillary thyroid carcinoma (PTC).Based on the somatic mutation data of 487 PTC patients from The Cancer Genome Atlas (TCGA), TMB was calculated, and we classified the samples into high-TMB (H-TMB) and low-TMB (L-TMB) groups. Bioinformatics methods were used to explore the characteristics and potential mechanism of TMB in PTC.High TMB predicts shorter progression-free survival (PFS) (P < 0.001). TMB was positively correlated with age, stage, tumor size, metastasis, the male sex and tall cell PTC. Compared to the L-TMB group, the H-TMB group presented with lower immune cell infiltration, a higher proportion of tumor-promoting immune cells (M0 macrophages, activated dendritic cells and monocytes) and a lower proportion of antitumor immune cells (M1 macrophages, CD8+ T cells and B cells). Additionally, the characteristics displayed by different TMB groups were not driven by critical driver mutations such as BRAF and RAS.PTC patients with high TMB have a worse prognosis. By stratifying PTC patients according to their TMB, advanced PTC patients who are candidates for immunotherapy could be selected.